About Kintara Therapeutics

About Kintara Therapeutics

Kintara Therapeutics is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a first-in-class small molecule chemotherapy that is currently being evaluated in a Phase 2 clinical trial for the treatment of refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 as a therapy for front-line GBM and solid tumors including non-small cell lung cancer (NSCLC) and ovarian cancer.

We have acquired certain exclusive commercial rights in China where VAL-083 is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer.

Learn More about Kintara Therapeutics

About the Clinical Trials

VAL-083 is a structurally unique, "first-in- class", small-molecule chemotherapeutic. Based on historical data and our own research, we believe that VAL-083 has the potential to offer physicians and patients a new paradigm in the treatment of Glioblastoma Multiforme (GBM).

The purpose of this Phase 2, open-label, single-arm study is to determine the safety and the

For Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression: More Information

The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and

For Patients With Recurrent Malignant Glioma: More Information

The safety and efficacy of the investigational use of this product has not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.